Skip to main content
PMC home page
Springer logoLink to Springer
. 2019 Jan 23;23(3):435. doi: 10.1007/s10157-019-01694-w

Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

Tetsuhiro Tanaka 1, Masaomi Nangaku 1, Enyu Imai 2, Yoshiharu Tsubakihara 3, Masatoshi Kamai 4, Michihito Wada 5, Shinji Asada 5,✉, Tadao Akizawa 6
PMCID: PMC6828206  PMID: 30673934

Correction to: Clinical and Experimental Nephrology 10.1007/s10157-018-1632-9

In the original publication of the article, two sentences in the “Results” section were published incorrectly. The corrected texts are provided below:

  1. In the first paragraph of the section “Effectiveness”, 10th line should read as “The administered dose of darbepoetin (mean ± SD, µg) in the effectiveness analysis”.

  2. In the fourth paragraph of the section “Effectiveness”, 1st line should read as “Female patients or those with advanced age…baseline systolic blood pressure ≥ 130 mmHg”.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Clinical and Experimental Nephrology are provided here courtesy of Springer

RESOURCES